Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

NCT03794336 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1293

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Alogliptin
DRUG: Acarbose
DRUG: Metformin
DRUG: Aspirin

Sponsor

Sanofi